Literature DB >> 30337796

Giant right coronary artery aneurysm secondary to Kawasaki disease in an infant.

Omer A Algonaid1, Abdulrahman S Almoukirish1, Yahya H Almashham1.   

Abstract

Kawasaki disease (KD) is a potentially decapacitating multisystemic vasculitis with unknown etiology that acquired worldwide attention due to associated coronary aneurysms leading to life-threatening complications in very young babies including thrombosis, ischemia, and rupture. High levels of suspicion for early diagnosis and prompt treatment are crucial in preventing serious complications. We report here one of the patients who developed a giant coronary aneurysm but fortunately not a life-threatening complication after 5 years of follow-up. We conclude that later intravenous immunoglobulins (IVIG) treatment could be an important factor-among others-that precipitate into such complications.

Entities:  

Keywords:  Coronary artery; Echocardiogram; Giant coronary artery aneurysm; Infant; Kawasaki disease

Year:  2018        PMID: 30337796      PMCID: PMC6187052          DOI: 10.1016/j.jsha.2018.08.004

Source DB:  PubMed          Journal:  J Saudi Heart Assoc        ISSN: 1016-7315


Introduction

Kawasaki disease (KD) was first described in Japan in 1961 by Dr. Tomisaku Kawasaki and is now encountered worldwide [1]. Onefourth of patients developed coronary dilatation but only ∼2% died suddenly after the acute stage due to myocardial infarction caused by acute thrombosis within coronary artery aneurysms or rarely from aneurysmal rupture [2]. The persistence of giant coronary artery aneurysms (with internal diameters >8 mm) decreases to 0.5% – 1% if the patients are treated adequately and in time [3]. A few small studies that addressed the incidence and prevalence of KD in Kingdom of Saudia Arabia showed no significant differences between national statistical data than what is observed worldwide [4], [5].

Case report

A 5-month-old infant was admitted to our center with a history of persistent fever for 3 weeks. She also had a history of polymorphic skin rash, red eyes, cracked lips, and skin peeling that started at the periungual area. She was treated with antibiotics for a suspected throat infection in a local hospital. At admission she was irritable with skin peeling on her toes and fingers. The initial laboratory findings showed hemoglobin 7.5 g/dL, white cell count (WBC) 16,200 (n = 36%, L = 48%, mono = 13%, others = 4%) platelets 1,356,000/mm, total protein 77 g/L [normal range (NR) 64–83 g/L] albumin 35 g/L (NR 35–50 g/L), erythrocyte sedimentation rate 43 mm/h (NR up to 20 mm/h), C-reactive protein 44.5 mg/L (NR 1–3 mg/L), prothrombin time (PT) 11 seconds (NR 11–15 seconds), activated partial thromboplastin time (aPTT) 33 seconds (NR 28–41 seconds), Beta-natriuretic peptide (BNP) 149 pmol/L (NR up to 15.3 pmol/L), and creatine kinase (CK) 42 U/L (NR 26–192 U/L). Sepsis workup including blood and urine cultures were unremarkable. Echocardiography did not show signs of ischemia. Echocardiography showed (Fig. 1A and B) gross dilatation of the left coronary artery with multiple large aneurysmal dilatations and a possible small clot, giant Right Coronary Artery aneurysm, preserved LV systolic function, and moderate pericardial effusion (PE) without signs of tamponade.
Figure 1

Short axis parasternal echocardiographic view showing (A) a giant Right Coronary Artery and multiple LCA aneurysms and (B) multiple Left Coronary Artery aneurysms.

Short axis parasternal echocardiographic view showing (A) a giant Right Coronary Artery and multiple LCA aneurysms and (B) multiple Left Coronary Artery aneurysms. Five days after admission; CKMB/CK was 28/31 U/L (NR for CKMB up to 25 U/L) and Troponin T was 27 ng/L (NR = up to 14 ng/L). CT angiography confirmed the echocardiography findings. Even though it was a late treatment the patient received one dose of IVIG 2 g/kg, and kept on aspirin 5 mg/kg/day, heparin 20 IU/Kg/hr with target aPTT 50–60 seconds, and warfarin 1 mg orally once daily with a target international Normalization Ratio (INR) of 2–3. After 16 days of warfarin, the medication was changed to enoxaparin S/C 1 mg/kg/dose 12 hourly due to difficulty to keep the target INR range. The patient remained clinically stable and serial echocardiography revealed persistent giant RCA aneurysm with formation of small shell of thrombosis appearing anteriorly, and gradual improvements of LCA dilatations and aneurysms, as well as normalization of other laboratory tests. The patient was not found to be a candidate for additional therapy and was therefore discharged on aspirin and enoxaparin and followed up in the outpatient department (OPD). Then at the age of 18 months the patient was admitted electively for cardiac catheterization as part of a giant coronary aneurysm follow up. Coronary angiography showed giant RCA aneurysm (19.9 × 26 mm) with fusiform medium sized LAD aneurysm (6.9 × 10.2 mm) (see Fig. 2) but no coronary obstruction.
Figure 2

Aortic root angiography showing a giant Right Coronary Artery with a small Left Anterior Descending artery aneurysm.

Aortic root angiography showing a giant Right Coronary Artery with a small Left Anterior Descending artery aneurysm. The patient was followed up in the OPD and on the last visit at 5 years and 5 months of age the patient was doing well. Echocardiography showed persistent giant right coronary artery aneurysm (diameter 18 mm) with a small old organized anterior shell of thrombosis and mildly dilated left main coronary artery but no aneurysm or thrombosis and normal function.

Discussion

The true incidence of KD in Middle Eastern countries is not known. The incidence was 7.4 per 100,000 children under 5 years of age in a retrospective study conducted in an eastern province of Saudi Arabia for the period from 1992 to 2012 [5], [6]. KD is associated with increasing complications in infants. Many risk factors contribute to the increased risk of coronary aneurysm especially delayed IVIG administration, age <6 months, saccular shape of coronary aneurysm, and its giant size (>8 mm diameter) [1], [7]. We reported an infant with KD who received IVIG after >2 weeks and already had a persistent giant saccular RCA aneurysm whereas LCA multiple fusiform aneurysms improved with time (see Fig. 3).
Figure 3

Short axis parasternal echocardiographic view shows an improved Left Coronary Artery aneurysm and persistent RCA aneurysm.

Short axis parasternal echocardiographic view shows an improved Left Coronary Artery aneurysm and persistent RCA aneurysm. Burns et al. [11] reported that infliximab made 13/16 patients with IVIG-resistant KD defervescent and their laboratory measures improved within 48 hours [8] However, our patient was admitted after the acute stage had already ensued. Warfarin is a good choice for complicated KD patients who need additional anticoagulation. However, this oral anticoagulant may be substituted with daily subcutaneous injections of enoxaparin in case of failure to maintain a safe therapeutic INR level [7], [8], [9], [10]. The indications for revascularization surgery (coronary bypass graft procedures) in children have not been established in clinical trials, but such surgery should be considered when reversible ischemia is present on stress testing [7], [8], [10]. Our patient could not undergo stress testing as she was uncooperative.

Conclusion

Kawasaki disease is a debilitating disease which needs prompt and early action with regard to treatment with IVIG to prevent lifelong disability and complications [7], [8], [10]. A large scale epidemiologic data of KD however are not available for KSA. According to our knowledge this is the first giant coronary aneurysm clearly related to KD reported in KSA that persisted for 5 years fortunately with an uneventful course.
  8 in total

Review 1.  Kawasaki disease: etiology, pathogenesis, and treatment.

Authors:  Karyl S Barron
Journal:  Cleve Clin J Med       Date:  2002       Impact factor: 2.321

2.  Intracoronary thrombus in an infant with Kawasaki disease and giant coronary aneurysm.

Authors:  Milad El-Segaier; Mo Galal
Journal:  Acta Paediatr       Date:  2013-02-18       Impact factor: 2.299

3.  Giant right coronary artery aneurysm secondary to Kawasaki disease in child: a case report.

Authors:  Shanshan Zhang; Geli Liu; Tielian Yu; Guiming Zhou; Rongxiu Zheng
Journal:  Int J Clin Exp Pathol       Date:  2015-08-01

4.  Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association.

Authors:  Jane W Newburger; Masato Takahashi; Michael A Gerber; Michael H Gewitz; Lloyd Y Tani; Jane C Burns; Stanford T Shulman; Ann F Bolger; Patricia Ferrieri; Robert S Baltimore; Walter R Wilson; Larry M Baddour; Matthew E Levison; Thomas J Pallasch; Donald A Falace; Kathryn A Taubert
Journal:  Circulation       Date:  2004-10-26       Impact factor: 29.690

5.  Infliximab treatment for refractory Kawasaki syndrome.

Authors:  Jane C Burns; Wilbert H Mason; Sarmistha B Hauger; Hillel Janai; John F Bastian; Julie D Wohrley; Ian Balfour; Cynthia A Shen; Edward D Michel; Stanford T Shulman; Marian E Melish
Journal:  J Pediatr       Date:  2005-05       Impact factor: 4.406

6.  Kawasaki disease in Western Saudi Arabia.

Authors:  Khalid M Al-Harbi
Journal:  Saudi Med J       Date:  2010-11       Impact factor: 1.484

7.  Kawasaki disease in infants less than one year of age.

Authors:  E A Rosenfeld; K E Corydon; S T Shulman
Journal:  J Pediatr       Date:  1995-04       Impact factor: 4.406

Review 8.  Management of Kawasaki disease.

Authors:  D Eleftheriou; M Levin; D Shingadia; R Tulloh; N J Klein; P A Brogan
Journal:  Arch Dis Child       Date:  2013-10-25       Impact factor: 3.791

  8 in total
  1 in total

1.  COVID-19-Related Giant Coronary Aneurysms in an Infant with Multisystem Inflammatory Disorder in Children: The First Case Report from the United Arab Emirates and the Arab Region.

Authors:  Ghassan Ghatasheh; Huda Al Dhanhani; Ashutosh Goyal; Muhammad Bassel Noureddin; Doaa Al Awaad; Ziad Peerwani
Journal:  Case Rep Infect Dis       Date:  2021-01-18
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.